News

Unilabs acquires CGC Genetics, a leading Medical Genetics Laboratory company in Portugal

6/20/2017
​​​​

Geneva, Porto 20th June 2017. Geneva based Unilabs today announced that it has reached an agreement to acquire CGC Genetics, a leading Medical Genetics Laboratory company serving customers in more than 65 countries, for an undisclosed amount from private equity firm Vallis Capital Partners.

CGC Genetics has grown to become one of the most advanced European Medical Genetics Laboratory providers, serving customers globally. The company is a reference for Medical Genetics testing, offering a full service of Medical Genetic testing solutions for its customers.

Jos Lamers, CEO of Unilabs said: “CGC has made an impressive journey to build its position as a pivotal player in the Medical Genetic Laboratory markets, with a worldwide footprint. This operation reflects our strategic focus on reinforcing Unilabs’ Reference and Special Testing Portfolio. We lookforward to welcoming CGC Genetics into the Unilabs family.”

Eduardo Rocha, CEO of Vallis Capital Partners added: “We are very proud to have been part of the CGC Genetics success story since our Fund Vallis Sustainable Investments I invested in the company in 2014. Our chief strategic goal was to leverage the exceptional skill set of CGC Genetics which combined with the investment in state-of-the-art technology was the foundation for a growth cycle through international expansion. We are now confident that CGC Genetics will continue to thrive in a new growth cycle within the Unilabs environment.”

Prof. Purificação Tavares, CEO of CGC Genetics commented: “We believe we have found a true strategic partner in Unilabs, and I would like to thank Vallis Capital Partners for helping CGC Genetics getting to the next level. Within Unilabs we have a tremendous opportunity to accelerate our growth via the exchange of best practices and the support of an internationally recognised brand and contribute to expanding Unilabs’ capabilities for the benefit of all its customers.”

 

CONTACTS

 For further information or to arrange an interview with Unilabs, please contact Pauline Kropp at media@unilabs.com or +41 22 909 77 94

ABOUT UNILABS

With over 196 laboratories and 44 imaging units and a broad catalogue of more than 2,500 diagnostic tests, Unilabs is one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services. Headquartered in Geneva, Switzerland the Unilabs Group serves private and public healthcare providers, local governments, pharmaceutical companies and the general public. The company employs more than 6,800 people worldwide, successfully operates laboratory and medical diagnostic imaging facilities in 14 countries, and generates annual revenues of €790m in 2016. Its network of facilities provides its customers with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe.

 

We are at the heart and start of all effective treatment decisions!


Please visit
www.unilabs.com and follow us on Twitter

 

 

About CGC Genetics
Founded in 1992, CGC Genetics is a reference laboratory for genetic diagnostic testing. Performing more than 4000 different genetic tests, available for all medical specialties, all performed at the vanguard of technology and supervised by Medical Geneticists. CGC Genetics is a leading laboratory in clinical genetics in Europe, receiving samples from all over the world, including hospitals, public and private, medical clinics, insurance companies, universities and research centers.

About Vallis Capital Partners

An independent Private Equity firm, fully owned by its Founding Partners endorsing the intrinsic long-term value creation based on a proactive ownership and a "hands on" approach to its portfolio companies. Through its Fund Vallis Sustainable Investments I, invests in Iberian SME’s with high growth potential, whose demand drivers are strongly correlated with medium and long term sustainable trends, creating value for investors while contributing to a more Sustainable World. The Fund is currently invested in the largest producer of raspberries, Hubel Agrícola, in the largest Portuguese chain of dental clinics, Smile-Up, in the renowned chocolate producer, Imperial, in the most advanced eCommerce platform for public tendering, Vortal, in the producer of soap and other luxury scented products, Castelbel, in the producer of healthy gummies, DoctorGummy, and in the producer of disposable medical products, Raclac. Vallis Capital Partners is a Socially Responsible Investor and was the first Portuguese asset management company to have become a signatory of the "Principles for Responsible Investment" (PRI) of the United Nations. ​​​​